News & Blog

Mechanisms, Markers, and Risk Factors in Friedreich’s Ataxia Heart Disease (FA-HD)

Characterization of the Cardiac Phenotype of Friedreich’s Ataxia

Biomarkers in Friedreich’s Ataxia

A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants with Friedreich’s Ataxia Aged 2 to 15 Years Old (BRAVE)

TRACK-FA: A Natural History Study to TRACK Brain and Spinal Cord Changes in Individuals with Friedreich’s ataxia

NAD+ and Exercise in FA (ExRx in FA) – Nicotinamide Riboside (NR)

Omaveloxolone Dose Finding Study in Children With Friedreich’s Ataxia (BOLD)

Gene Therapy for Cardiomyopathy Associated with Friedreich’s Ataxia – LX2006

A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia

A Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich Ataxia (MOVE-FA)

A Study of Vatiquinone for the Treatment of Participants with Friedreich’s Ataxia

A Pilot Investigator Initiated Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide in the Treatment of Advanced Symptoms of Friedreich Ataxia (FRDA)